U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110519) titled 'Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol' on July 31.
Brief Summary: This is a Phase 0 interventional, non-therapeutic study investigating the biodistribution and safety of [18F]-fluoromannitol as a radiotracer (a substance used to help detect disease or infection) in Positron Emission Tomography (PET) scans.
The primary objective of this study is to generate safety data in healthy adult human volunteers. In the future, this tracer may help to determine if a medical problem is infectious in people who have Sickle Cell Disease, cancer or other conditions that impact the immune system...